KMT2A and acute myeloid leukemia: Currently, two phase 1/2 clinical trials are evaluating the menin inhibitors KO-539 (NCT04067336) and SNDX-5613 (NCT04065399) in adult patients with relapsed/refractory AML or MLL-rearranged/NPM1-mutated AML, respectively.